Benzodiazepine Dependence

What Benzodiazepines Do

Benzodiazepines — Xanax, Klonopin, Valium, Ativan, and others — are among the most widely prescribed psychiatric medications, and among the least understood by the people taking them. They work by amplifying the activity of GABA, the brain’s primary inhibitory neurotransmitter, at a specific receptor called the GABA-A receptor. The result is increased calming activity throughout the brain and nervous system, producing sedation, anxiety relief, muscle relaxation, and a reduction in seizure risk.

They are effective in the short term. The problem is neuroadaptation. With sustained use, GABA-A receptor subunit composition shifts — receptors are internalized, downregulated, and become progressively less sensitive to GABA stimulation. The brain simultaneously ramps up its excitatory activity, attempting to compensate for chronic inhibitory suppression. Over time, this compensation erodes. What results is not a stable new baseline but an active dysregulation: two overdriven systems that have lost their coordination with one another, producing a nervous system that is no longer reliably self-regulating. The original problem has not been treated — it has been chemically overridden while the underlying disruption compounds.

What Benzodiazepine Withdrawal Involves

Benzodiazepine withdrawal is medically serious and consistently underestimated — including by the physicians who prescribe these medications. Like alcohol withdrawal, it involves the sudden unmasking of a profoundly upregulated excitatory nervous system that has been held in check by the drug’s chronic suppression of GABA activity. Seizures, and in serious cases a prolonged seizure state that requires emergency treatment, are genuine risks, not remote ones. More commonly, withdrawal produces intense and lasting anxiety, insomnia, cognitive difficulties, perceptual disturbances, and physical symptoms that can be disabling. There is also a kindling effect: each failed or too-rapid attempt to stop sensitizes the nervous system further, so that subsequent withdrawals become more severe. This is one reason why the history of prior taper attempts is an important part of the clinical picture — and why a carefully managed taper, paced to what the nervous system can actually tolerate, is a different undertaking than the attempts that didn’t hold.

This is sometimes called protracted withdrawal or Post-Acute Withdrawal Syndrome (PAWS) — but that framing implies two distinct phases where there is really one continuous process of the brain finding its way back — one that cannot be rushed. Anxiety, cognitive fog, dysphoria, gastrointestinal disturbances, and unusual body sensations that persist long after the last dose are not a complication or an unusual outcome. They are a predictable consequence of how thoroughly the nervous system has been reorganized. This is precisely why the taper is slow and gradual: to avoid outpacing the brain’s capacity to readapt, and to minimize any of these symptoms throughout the process.

How I Approach It

Treatment almost always begins with conversion to a longer-acting benzodiazepine — most often diazepam (Valium), which stays in the body longer and clears more gradually, making it more amenable to a controlled taper than shorter-acting agents like Xanax or Ativan, which produce sharper fluctuations in how the drug acts on the brain. This is the basis of the Ashton Manual, which has the most clinical evidence behind it for benzodiazepine tapering.

The neurological changes that developed over years of use cannot be reversed quickly. Rapid reduction recreates the excitatory storm that makes withdrawal dangerous and symptomatic. A gradual, individually calibrated taper works because the pace is the treatment: two overactive systems that have lost their coordination cannot be rushed back into balance. Each small reduction asks the nervous system to begin recalibrating, and requires time to consolidate before the next step. This is why the taper is slow — usually a year or two, sometimes considerably longer, depending on the duration of use, the dose, and the clinical picture.

The work alongside the taper is as important as the taper itself. Benzodiazepine dependence rarely exists in isolation — in most cases there is a legitimate underlying condition that was never properly treated, only chemically suppressed. What that condition actually is, and what the medication has been doing, is not always what it appears to be on the surface — or what the patient has been told. As the taper proceeds, those questions need to be understood and addressed: how the condition developed, what it has required, and what a different relationship with those experiences might look like. One particular complexity is that the symptoms of withdrawal often resemble, or are difficult to distinguish from, the condition the medication was originally prescribed for — whatever that was. Patients often find it genuinely difficult to distinguish what belongs to what, and that confusion is itself something the work can help clarify over time. The taper creates the conditions for that work. Neither is sufficient without the other.

Frequently Asked Questions

Q: Can the taper be done while continuing to work and live normally?

A: For most people, yes. The taper is designed to be slow enough that the nervous system is never asked to do more than it can manage at a given moment. That pace is not incidental — it is what allows most people to continue working, maintaining relationships, and living their lives throughout the process. There will likely be periods that are harder than others, and those are addressed as they arise. But the goal of a carefully managed taper is precisely to avoid the kind of acute disruption that makes normal functioning impossible.

Q: What if I’m currently being prescribed benzodiazepines by another doctor?

A: This is a common situation and not an obstacle to getting in touch. Many people seeking help with benzodiazepine dependence are still under the care of the physician who originally prescribed the medication — often a primary care doctor or psychiatrist who may not have recognized that dependence had developed, or who may not have a clear plan for addressing it. You do not need to notify that doctor before calling, and nothing about an initial conversation creates any obligation. If treatment here moves forward, however, it would require transferring your care — having two physicians managing overlapping treatment creates risks that responsible medicine cannot accommodate.

Q: What if I’m taking other psychiatric medications alongside benzodiazepines?

A: That is very common. Benzodiazepines are frequently prescribed alongside antidepressants, mood stabilizers, sleep medications, and other psychiatric drugs — sometimes for years. Other medications do not preclude treatment here. They are part of the clinical picture that needs to be understood from the beginning, and how they interact with the taper is something that gets worked out carefully as treatment proceeds.

Q: What is the Ashton Manual?

A: The Ashton Manual is a clinical protocol developed by Professor Heather Ashton, a British psychopharmacologist who spent decades studying benzodiazepine dependence and its treatment. It involves converting from a shorter-acting benzodiazepine to diazepam (Valium), which stays in the body longer and clears more gradually, providing a more stable and manageable platform for a slow taper. It has the most clinical evidence behind it for benzodiazepine tapering and is the basis of the approach used here.

Q: How long does the taper take?

A: Usually a year or two, sometimes considerably longer, depending on the duration of use, the dose, and the individual’s clinical picture. The nervous system cannot be hurried back into balance — the changes that accumulated over years of use require time to reverse. A taper that moves faster than the brain can adapt doesn’t shorten the process; it derails it. The pace is not a limitation of the treatment. It is the treatment.

Q: Why can symptoms persist so long?

A: Because neurological readaptation is one continuous process, not two distinct phases. What is sometimes called protracted withdrawal is not a separate condition following an acute one — it is the same process of reorganization unfolding over a year or more. Anxiety, cognitive fog, dysphoria, gastrointestinal disturbances, and unusual body sensations that persist long after the last dose are a predictable consequence of how thoroughly the nervous system has been reorganized, not a sign that something has gone wrong or that the original condition has returned.

Q: Can stopping benzodiazepines be dangerous?

A: Yes. Abrupt discontinuation after significant use can provoke seizures and, in the worst cases, a prolonged seizure state that requires emergency treatment. More commonly, stopping too quickly produces intense anxiety, insomnia, cognitive difficulties, and physical symptoms that can seriously interfere with daily life — and through a process called kindling, each failed or too-rapid attempt sensitizes the nervous system further, making subsequent attempts harder. This is not a brief process, and a slow, gradual, medically managed taper is essential to getting through it safely.

Q: I’ve tried to stop before and it didn’t work. Does that make things harder?

A: Prior attempts are an important part of the clinical picture — understanding what happened, and why, shapes what a successful taper actually requires. Each too-rapid or failed attempt sensitizes the nervous system through a process called kindling, leaving it more reactive than before. This means the history is not a reason for discouragement but a reason for care: it tells us something specific about what this particular taper needs to account for.

Getting in Touch

If what you’ve read here describes your situation, I’d be glad to speak with you. The first conversation is free, completely confidential, and carries no obligation of any kind — just a chance to talk about what’s been happening and whether this might be the right fit.

Call directly: (646) 418-7077